Low muscle mass measured at T12 is a prognostic biomarker in unresectable oesophageal cancers receiving chemoradiotherapy
Name:
37385375.pdf
Size:
777.6Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
McSweeney, Donal MRaby, Sophie
Radhakrishna, Ganesh
Weaver, Jamie M
Green, Andrew
Bromiley, P. A.
van Herk, Marcel
McWilliam, Alan
Affiliation
Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UKIssue Date
2023
Metadata
Show full item recordAbstract
Background and purpose: Low muscle mass is an imaging biomarker of patient frailty that has been associated with increased toxicity and decreased survival in a number of cancers. Patients with unresectable oesophageal cancer receive chemoradiotherapy as standard of care. Muscle mass is not yet an established prognostic marker in this population. Muscle mass is usually assessed by segmenting skeletal muscle at the L3 vertebral level. But radiotherapy planning scans for oesophageal cancers do not always image this level, which has limited previous studies of body composition. Skeletal muscle is known to regulate immune function, but the association of muscle mass with lymphopenia in cancer patients has not been shown. Materials and methods: We retrospectively analyse 135 oesophageal cancer patients who received chemoradiotherapy and investigate the prognostic value of skeletal muscle area assessed at T12. We also examine the association between muscle mass and radiation-induced lymphopenia. Results: We find that low muscle mass is associated with poorer overall survival (hazard ratio [95% confidence interval]: 0.72 [0.53-0.97]). However, this effect interacts with body mass index (BMI) such that the prognostic value of low muscle mass is removed by high BMI. In our study, patients with low muscle mass were more prone to radiation-induced lymphopenia (75% vs. 50% in patients with high muscle mass). A significant decrease in circulating lymphocytes was associated with poorer overall survival (hazard ratio [95% confidence interval]: 0.68 [0.47-0.99]). Conclusion: Our study shows that assessing muscle mass at T12 is feasible and provides prognostic information. Low muscle mass at T12 is associated with poorer overall survival and increased risk of radiation-induced lymphopenia. Muscle mass provides additional information over performance status and BMI. Low BMI patients are most affected by low muscle mass, highlighting the importance of close nutritional support in this population.Citation
McSweeney DM, Raby S, Radhakrishna G, Weaver J, Green A, Bromiley PA, et al. Low muscle mass measured at T12 is a prognostic biomarker in unresectable oesophageal cancers receiving chemoradiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2023 Jun 27;186:109764. PubMed PMID: 37385375. Epub 2023/06/30. eng.Journal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2023.109764PubMed ID
37385375Additional Links
https://dx.doi.org/10.1016/j.radonc.2023.109764Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2023.109764
Scopus Count
Collections
Related articles
- Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
- Authors: Panje CM, Höng L, Hayoz S, Baracos VE, Herrmann E, Garcia Schüler H, Meier UR, Henke G, Schacher S, Hawle H, Gérard MA, Ruhstaller T, Plasswilm L, Swiss Group for Clinical Cancer Research (SAKK)
- Issue date: 2019 Sep 11
- Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer.
- Authors: Mallet R, Modzelewski R, Lequesne J, Mihailescu S, Decazes P, Auvray H, Benyoucef A, Di Fiore F, Vera P, Dubray B, Thureau S
- Issue date: 2020 May 22
- Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapy.
- Authors: Jang JY, Oh D, Noh JM, Sun JM, Kim HK, Shim YM
- Issue date: 2024 Jun
- Comparison of CT derived body composition at the thoracic T4 and T12 with lumbar L3 vertebral levels and their utility in patients with rectal cancer.
- Authors: Arayne AA, Gartrell R, Qiao J, Baird PN, Yeung JM
- Issue date: 2023 Jan 16
- Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
- Authors: Kim IH, Choi MH, Lee IS, Hong TH, Lee MA
- Issue date: 2021 Jan 18